GPT and primary biliary cholangitis: In conclusion, in patients with PBC having an inadequate biochemical response to UDCA, tropifexor was generally safe and well tolerated at daily doses of 30–90 μg; tropifexor showed dose-dependent improvement in cholestatic markers GGT and ALP and the hepatocellular injury marker ALT and had higher exposure than that in healthy volunteers most likely owing to increased absorption.